Source: Optimer Pharmaceuticals, Inc.
Monday, October 19, 2009
advertisement
You do not have JavaScript enabled or are using an older version of
Adobe Flash. You can update your version of Adobe Flash here.
SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
"Age, Serum Albumin, and Leukocytosis/Fever Predict Clinical Outcomes of
Clostridium difficile Infection Treated with Fidaxomicin and Vancomycin"
Poster Presentation: Mark A. Miller, M.D.
Friday, October 30, 2009 12:30pm-2:00pm Eastern Time
Poster session: 053, Hospital-acquired and Transplant Infections
Presentation #: 420
"Faster Time to Resolution of Diarrhea with Fidaxomicin vs. Vancomycin in
Patients with Clostridium difficile Infection"
Poster Presentation: Mark A. Miller, M.D.
Friday, October 30, 2009 12:30pm-2:00pm Eastern Time
Poster session: 053, Hospital-acquired and Transplant Infections
Presentation #: 422
"Effect of Concomitant Antibiotics on Treatment of Clostridium difficile
Infection with Fidaxomicin or Vancomycin"
Poster Presentation: Kathleen M. Mullane, D.O.
Saturday, October 31, 2009 12:30pm-2:00pm Eastern Time
Poster session: 110, Late Breaker Posters
Presentation #: LB-14
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Porter Novelli Life Sciences
Jason I. Spark, Vice President
619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
CONTACT: Christina Donaghy, Corporate Communications Manager, or John D.
Prunty, Chief Financial Officer & VP Finance, both of Optimer
Pharmaceuticals, Inc., +1-858-909-0736; or Jason I. Spark, Vice President
of Porter Novelli Life Sciences, +1-619-849-6005, for Optimer
Pharmaceuticals, Inc.
Web site: http://www.optimerpharma.com/